Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 10/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13334309 | 1.00 | MEN1 (0.50) | MEN1KMT2ANPSR1TSHRCYP3A4 | |
| SCHEMBL2752094 | 1.00 | MEN1 (0.50) | MEN1KMT2ANPSR1TSHRCYP3A4 | |
| SCHEMBL16859361 | 0.89 | MEN1 (0.56) | MEN1KMT2ANPSR1TSHRCYP3A4 | |
| SCHEMBL2752953 | 0.89 | MEN1 (0.56) | MEN1KMT2ANPSR1TSHRCYP3A4 | |
| SCHEMBL16859362 | 0.88 | TSHR (0.50) | MEN1KMT2ANPSR1TSHRCYP3A4 | |
| SCHEMBL2751440 | 0.85 | ALDH1A1 (0.55) | MEN1KMT2ANPSR1TSHRCYP3A4 | |
| SCHEMBL16859363 | 0.85 | ALDH1A1 (0.55) | MEN1KMT2ANPSR1TSHRCYP3A4 | |
| SCHEMBL2751785 | 0.81 | TSHR (0.60) | MEN1KMT2ANPSR1TSHRCYP3A4 | |
| SCHEMBL28731719 | 0.81 | ALDH1A1 (0.47) | MEN1KMT2ANPSR1TSHRCYP3A4 | |
| SCHEMBL27683601 | 0.76 | ACP3 (0.56) | MEN1KMT2ANPSR1LMNAACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193743-B2 | Method of enantioselective addition to imines | NATIONAL TSING HUA UNIVERSITY (TW) | 2015-11-24 | — | — | US | disclosed |
| US-9193743-B2 | Method of enantioselective addition to imines | NATIONAL TSING HUA UNIVERSITY (TW) | 2015-11-24 | — | — | US | disclosed |
| US-9193743-B2 | Method of enantioselective addition to imines | NATIONAL TSING HUA UNIVERSITY (TW) | 2015-11-24 | — | — | US | disclosed |
| US-20150183811-A1 | METHOD OF ENANTIOSELECTIVE ADDITION TO IMINES | NATIONAL TSING HUA UNIVERSITY (TW) | 2015-07-02 | — | — | US | disclosed |
| US-20150183811-A1 | METHOD OF ENANTIOSELECTIVE ADDITION TO IMINES | NATIONAL TSING HUA UNIVERSITY (TW) | 2015-07-02 | — | — | US | disclosed |
| US-20150183811-A1 | METHOD OF ENANTIOSELECTIVE ADDITION TO IMINES | NATIONAL TSING HUA UNIVERSITY (TW) | 2015-07-02 | — | — | US | disclosed |
| EP-1210305-B1 | TRANSFER HYDROGENATION PROCESS | AVECIA PHARMACEUTICALS LTD (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6696608-B1 | PRODUCING PRIMARY OR SECONDARY AMINES FROM N-SUBSTITUTED IMINES AND IMINIUM SALTS | AVECIA LIMITED (GB) | 2004-02-24 | — | — | US | disclosed |
| EP-1210305-A1 | TRANSFER HYDROGENATION PROCESS | Avecia Limited (GB) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012574-A1 | TRANSFER HYDROGENATION PROCESS | AVECIA LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183811-A1 | METHOD OF ENANTIOSELECTIVE ADDITION TO IMINES | INMT, H1-4, INSR | MEN1 600/4885KMT2A 271/4885NPSR1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.